The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 8 of the 20 sources its claims cite were checked for support.
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron
Open accessAbstract
The iron-regulatory hormone hepcidin is induced early in infection, causing iron sequestration in macrophages and decreased plasma iron; this is proposed to limit the replication of extracellular microbes, but could also promote infection with macrophage-tropic pathogens. The mechanisms by which hepcidin and hypoferremia modulate host defense, and the spectrum of microbes affected, are poorly understood. Using mouse models, we show that hepcidin was selectively protective against siderophilic extracellular pathogens (Yersinia enterocolitica O9) by controlling non-transferrin-bound iron (NTBI) rather than iron-transferrin concentration. NTBI promoted the rapid growth of siderophilic but not nonsiderophilic bacteria in mice with either genetic or iatrogenic iron overload and in human plasma. Hepcidin or iron loading did not affect other key components of innate immunity, did not indiscriminately promote intracellular infections (Mycobacterium tuberculosis), and had no effect on extracellular nonsiderophilic Y enterocolitica O8 or Staphylococcus aureus Hepcidin analogs may be useful for treatment of siderophilic infections.
Overview
CoChat Summary
TL;DR
Hepcidin protects mice against the siderophilic extracellular pathogen *Yersinia enterocolitica* O9 by clearing non–transferrin-bound iron (NTBI), not by lowering transferrin-bound iron. Hepcidin agonists (minihepcidins) rapidly eliminate NTBI and treat NTBI-dependent infection even when started after symptoms appear.
Key findings
- Hepcidin-1 knockout (HKO) mice had inoculum-dependent mortality after oral *Y. enterocolitica* O9, reaching 100% at 10^8 CFU by day 6, whereas wild-type mice had 0% mortality at all inocula tested. Iron-depleted HKO mice were completely protected, while iron-loaded HKO mice had 100% mortality, indicating protection depended on systemic iron availability rather than direct antimicrobial hepcidin activity.
- Hepcidin/iron status did not alter catheter-associated *Staphylococcus aureus* infection, nonsiderophilic *Y. enterocolitica* O8 infection, or pulmonary *Mycobacterium tuberculosis* burden at 5 and 10 weeks.
- NTBI was detectable only in iron-loaded WT and HKO mice and correlated with yersiniosis susceptibility; serum NTBI <2 µM correlated with nonlethal systemic infection, while NTBI >2 µM associated with lethal *Y. enterocolitica* O9 infection.
- Minihepcidin PR7310 reduced serum iron and ablated NTBI, nearly eliminating bacterial dissemination; in a replicate survival experiment, all solvent-treated mice died by day 8 versus >80% survival in minihepcidin-treated mice. Delayed treatment started on day 2 or day 3 after infection yielded 100% and 70% survival by day 21, respectively.
Methods
- Mouse models on C57BL/6 background included wild-type, hepcidin-1 knockout (HKO), LysEGFP, and HKO/LysEGFP mice. Iron depletion used a 4-ppm Fe diet for 6–8 weeks; iron loading used intraperitoneal 20 mg iron dextran. Minihepcidin treatment was 100 nmol PR7310 or solvent by intraperitoneal injection daily.
- Infections used *Y. enterocolitica* O9 strain Ruokola/71 and O8 strain WA by oral gavage or intraperitoneal injection (10^4–10^8 CFU/mouse), bioluminescent *S. aureus* Xen36 in a catheter-associated model, and aerosol *M. tuberculosis* Erdman at 30 CFU/mouse with assessment at 5 and 10 weeks.
- NTBI was measured by enhanced labile plasma iron (eLPI) assay. In vitro growth assays used human plasma agar with 0–60 µM ferric ammonium citrate for *Y. enterocolitica* and liquid human plasma with 0–100 µM ferric ammonium citrate, holotransferrin, or apotransferrin for *Vibrio vulnificus*. Statistics included Student t test, Mann-Whitney rank sum, 2-way ANOVA, Kaplan-Meier/log-rank, and χ2 tests.
Limitations
- The paper states that inbred animal models are an imperfect representation of complex human conditions and that the proposed mechanisms and therapeutic applications need further testing and refinement in human clinical studies.
- The paper states that it remains to be determined which specific forms of NTBI in circulation stimulate rapid growth of siderophilic pathogens, and that testing of additional infection models is needed to determine whether hepcidin-mediated changes in transferrin saturation control other microbes.
- The methods state that researchers were not blinded to treatment group; evident from the text, the findings are proof-of-concept in mice and ex vivo human plasma, with no human clinical outcomes reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“We previously showed that hepcidin is critical for mouse survival in V vulnificus infection,10”
What the sources say
- Supportedcites [10] Arezes, 2015, Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus, Cell Host Microbe source
The Results section, “Hepcidin is required for resistance to V. vulnificus infection” (Figure 1A–B; page not provided), reports that hepcidin-knockout mice died after infection under both iron-depleted and iron-loaded conditions, whereas wild-type mice survived at the tested inocula. This directly supports the claim that hepcidin is critical for mouse survival in this infection. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients with transfusional iron overload are also at increased risk of infections.8”
What the sources say
- Supportedcites [8] Porter, 2014, The pathophysiology of transfusional iron overload, Hematol Oncol Clin North Am source
The ‘Mechanisms of Iron Toxicity in Transfusional Overload’ section explicitly identifies increased infection risk as a consequence of iron overload. It also explains how transferrin saturation can make iron more available to microorganisms. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Hereditary hemochromatosis patients, who are iron-overloaded as a result of hepcidin deficiency, are more susceptible to infections with Escherichia coli,3 Vibrio vulnificus,4 Listeria monocytogenes,5 and Yersinia enterocolitica.6,7”
What the sources say
- Not checked — no full text of the sourcecites [6] Vadillo, 1994, Multiple liver abscesses due to Yersinia enterocolitica discloses primary hemochromatosis: three cases reports and review, Clin Infect Dis source
- Supportedcites [7] Capron, 1984, Spontaneous Yersinia enterocolitica peritonitis in idiopathic hemochromatosis, Gastroenterology source
The Discussion describes apparent susceptibility to Yersinia infection in patients with severe iron overload and identifies idiopathic hemochromatosis as an associated condition. It also advises suspecting Y. enterocolitica infection in febrile patients with iron overload, particularly those with idiopathic hemochromatosis. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to V vulnificus and Y enterocolitica strains, Klebsiella pneumoniae, a common cause of pneumonia and sepsis, also manifested NTBI-enhanced pathogenicity in our mouse models.26”
What the sources say
- Partly supportedcites [26] Michels, 2017, Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia, JCI Insight sourceExperimental — accuracy not yet measured
The section “Increased iron availability worsens the outcome of infection” reports that iron-treated mice with K. pneumoniae pneumonia had higher mortality and bacterial burdens. The paper links labile, non-transferrin-bound iron to K. pneumoniae growth in supplemented human plasma, but the cited mouse experiments report elevated plasma iron, not a measurement showing that NTBI specifically caused the worsened infection. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Deferoxamine has been associated with promoting bacterial growth in multiple studies,29,30 whereas deferiprone at lower concentrations (data not shown) stimulated Y enterocolitica growth in vitro.”
What the sources say
- Not checked — no full text of the sourcecites [29] Arifin, 2014, Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus, Microbes Infect source
- Supportedcites [30] Lesic, 2002, Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica, Antimicrob Agents Chemother source
The Results report that deferoxamine promoted growth of all five tested Y. enterocolitica strains on iron-poor agar. The Discussion also describes numerous clinical reports and earlier experimental work concerning deferoxamine’s effects on this bacterium, supporting the statement that the association has appeared in multiple studies. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
63 more claims · 1 with their cited sources checked
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 28
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on the studies in mouse models of iron overload [38,42], patients with siderophilic infections in the setting of genetic iron overload disorders or chronic liver disease may benefit from treatment with hepcidin agonists when these become available for human use.”
From Iron and infection (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hepcidin-1 knockout mice infected orally with the O9 strain of Yersinia enterocolitica also provided a faithful model of the corresponding human infection, manifesting disseminated abscess formation and a lethal course [38] while wild-type control mice were resistant to these bacteria.”
From Iron and infection (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The central contribution of hepcidin for nutritional immunity against extracellular microbes is illustrated by the increased susceptibility of Hamp deficient (Hamp−/−) mice to infection by extracellular Gram-negative bacteria, such as siderophilic Yersinia enterocolitica, Vibrio vulnificus or Klebsiella pneumonia (25–27).”
From Innate Nutritional Immunity (2018) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This form of “nutritional immunity” is particularly important in infections with gram negative bacteria and some fungi ([54,56,57,58].”
From Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis (2021) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the most important iron species that supports microbial growth is non-transferrin bound iron (NTBI) [54]”
From Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis (2021) · cites this paper as [54]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Ware, R. E., de Montalembert, M., Tshilolo, L., & Abboud, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30193-9 · Cited by 977
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Self-citationNon-transferrin bound iron: a key role in iron overload and iron toxicity
Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.014 · Cited by 654
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003) · Blood · doi:10.1182/blood-2003-03-0807 · Cited by 475
: overview and epidemiologic correlates
Bottone, E. J. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)80028-8 · Cited by 461
Iron-Source Preference of Staphylococcus aureus Infections
Skaar, E. P., Humayun, M., Bae, T., DeBord, K. L., & Schneewind, O. (2004) · Science · doi:10.1126/science.1099930 · Cited by 440
The high-pathogenicity island: an iron-uptake island
Carniel, E. (2001) · Microbes and Infection · doi:10.1016/s1286-4579(01)01412-5 · Cited by 253
Arezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P. A., Ganz, T., Nemeth, E., & Bulut, Y. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.001 · Cited by 227
Self-citation
Cited by
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Self-citationIron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
“102 Anemia, usually moderate and normocytic, is multifactorial, because of concomitant insufficient erythropoietin production and impaired early erythroid commitment.”
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Self-citationHepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis
Nemeth, E., & Ganz, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126493 · Cited by 540
“In affected patients who are not treated, NTBI is taken up avidly through alternative iron transporters [62] in the liver, pancreas, heart and endocrine glands, causing progressive tissue injury, organ failure, and even premature death.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., & Nemeth, E.
- Affiliations
- Molecular, Cellular, and Integrative Physiology Graduate Program and
- University of California, Los Angeles (US)
- Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute for Molecular Medicine, University of Oxford, Oxford, United Kingdom;
- University of Helsinki (FI)
- Corresponding author
- Bulut, Yonca
- Nemeth, Elizabeta
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-07-20
- Volume
- 130
- Issue
- 3
- Pages
- 245-257
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5520472
- OpenAlex
- W2611092877
- Semantic Scholar
- 34f637e93091be9761b3695c1d0a33654902503c
- Cited by
- 145
- References
- 33
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 12 · 2023: 13 · 2022: 19 · 2021: 18 · 2020: 20 · 2019: 21 · 2018: 16 · 2017: 3
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK090554, R01DK107309)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- hepcidin, non-transferrin-bound iron, innate immunity, infection resistance, hereditary hemochromatosis, iron metabolism, iron sequestration
- MeSH terms
- Animals, Binding, Competitive, Disease Models, Animal, Hemochromatosis, Humans, Iron, Mice, Inbred C57BL, Mycobacterium tuberculosis, Oligopeptides, Protein Binding, Staphylococcal Infections, Staphylococcus aureus, Transferrin, Yersinia enterocolitica, Gene Expression, Survival Analysis, Mice, Knockout, Iron Overload, Mice, Catheter-Related Infections, Disease Resistance, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. https://app.cochat.ai/papers/10.1182/blood-2017-03-772715
- The paper
- Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., & Nemeth, E. (2017). Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. https://doi.org/10.1182/blood-2017-03-772715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.